• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Nightingale Health

0.96 EUR

+4.82 %

4,711 following

HEALTH

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+4.82 %
-13.09 %
-38.08 %
-53.37 %
-56.94 %
-66.34 %
-3.24 %
-81.51 %
-81.44 %

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more
Market cap
58.26M EUR
Turnover
455.09K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
06.03.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Mikko Mäkinen and Nomad Invest Oy have taken a position in the company. Also, a certain former javelin thrower has appeared on the list. Here are all the new shareholders on the largest shareholders list: Owner / Name Number of Shares (HEALTH) Toivanen Capital Oy 100 916 Tuomas Valtteri...
yesterday
by Vouma
21
Continuation of the previous post. We will get the latest data from the 2025 annual report, shown in the table below. In that, Kirin and Mitsui have been in the “Corporations and others” category because it didn’t really change with the COR acquisition, and COR is naturally included...
5/30/2026, 9:43 AM
by Puutaheinää
10
Well, that would make 6.5 million shares traded on the OTC already. I wonder if the operation is finished yet, whatever it may be. Who bought the block?
9 hours ago
by Puutaheinää
6
Highlights from the article published by the University of Eastern Finland on May 28: "Demonstrating the effectiveness of preventive healthcare has traditionally required long follow-up studies spanning several years because diseases develop slowly. NMR metabolomics (NMR-metabolomiikka...
1 hour ago
by The Ugly Buckling
4
LinkedIn #proteomics #biomarkers #precisionmedicine #olink #nightingalehealth... At Nightingale Health, we are committed to helping researchers unlock deeper biological insights from human samples. We are excited to announce that we can now offer Olink Explore HT proteomics technology...
2 hours ago
by Puutaheinää
4
Yesterday, there was a volume of 2.1 million. Apparently, it is possible to execute block trades on the OTC market without them appearing as individual trades in that data. otcmarkets.com OTC Markets | Official site of OTCQX, OTCQB, OTCID and Pink Limited Markets
9 hours ago
3
Quite a few, including Cor, are taking a positive view of the company at this valuation level. In practice, Perk is selling for their own reasons while others are scooping up shares, presumably without insider information. Some are certainly looking for shorter-term returns, but ...
yesterday
by Cle
3
Read more on our forum
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 06.03.2026

Latest extensive report

Released: 13.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
16.9.
2026

Annual report '26

5.11.
2026

General meeting '26

9.3.
2027

Interim report Q2'27

Nightingale joins wellbeing services county research project
Analyst Comment5/29/2026, 6:46 AM by
Antti Siltanen

Nightingale joins wellbeing services county research project

Nightingale's risk screening selects participants for lifestyle coaching.

Nightingale Health
Press release5/28/2026, 8:00 AM

Nightingale Health joins South Savo Wellbeing Services County's preventive healthcare research project in Finland

Nightingale Health
Regulatory press release5/27/2026, 1:45 PM

Nightingale Health Plc’s financial reporting and Annual General Meeting in financial year 2026–2027

Nightingale Health

Join Inderes community

Research, tools and community to support better investment decisions.

FREE account
The market's most popular morning review
Analysts' recommendations and comments
Stock comparison and the investor discussion forum
PREMIUM account
All company reports and analyses
Premium content: model portfolio, insider transactions, Premium articles
Inderes MCP: Inderes data directly into your AI tools
Create account
New partnership for Nightingale
Analyst Comment5/25/2026, 6:11 AM by
Antti Siltanen

New partnership for Nightingale

The new memorandum of understanding will expand blood analysis to the longevity programs in Switzerland and South Africa as early as this summer.

Nightingale Health
Press release5/22/2026, 6:30 AM

Nightingale Health and Formula 100 Health partner in preventive health: Embedding multi-disease risk detection across longevity programmes in Switzerland and South Africa

Nightingale Health
Regulatory press release5/21/2026, 2:25 PM

Nightingale Health Plc – Managers’ Transactions – Olli Karhi

Nightingale Health
Regulatory press release5/18/2026, 10:02 AM

Nightingale Health Plc: Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act (Cor Group Oy)

Nightingale Health
US market roadmap for medical devices – a European perspective
Analyst Comment3/27/2026, 10:45 AM by
Antti Siltanen

US market roadmap for medical devices – a European perspective

Success in the US requires success in several sub-areas.

BioretecAiforia TechnologiesNightingale HealthNexstimOptomedRevenio GroupModulightBiohit
Nightingale H1'26: Research projects accelerate H2
Research3/6/2026, 9:44 AM by
Antti Siltanen

Nightingale H1'26: Research projects accelerate H2

Nightingale's major research projects will generate revenue in H2.

Nightingale Health
Nightingale, Webcast, Half-year financial report 1 July–31 December 2025
Webcast3/5/2026, 12:00 PM

Nightingale, Webcast, Half-year financial report 1 July–31 December 2025

Nightingale Health
Regulatory press release3/5/2026, 7:00 AM

Nightingale Health's half-year report: Delivering clinical value for healthcare and moving toward 50% revenue growth, supported by a strong sales pipeline

Nightingale Health
Nightingale H1'26 preview: Revenue still relies on research projects
Analyst Comment3/3/2026, 7:11 AM by
Antti Siltanen

Nightingale H1'26 preview: Revenue still relies on research projects

We expect revenue to grow, driven by research projects and the Terveystalo collaboration.

Nightingale Health
A step forward for Nightingale in New York
Analyst Comment2/10/2026, 6:50 AM by
Antti Siltanen

A step forward for Nightingale in New York

The New York laboratory permit allows tests to be offered to healthcare providers without separate FDA approval.

Nightingale Health
Regulatory press release2/9/2026, 7:30 PM

Inside information: Nightingale Health achieves major milestone in the United States: New York laboratory now holds a clinical laboratory permit from New York State

Nightingale Health
Another welfare services country is piloting Nightingale's technology
Analyst Comment12/18/2025, 5:54 PM by
Antti Luiro, Antti Siltanen

Another welfare services country is piloting Nightingale's technology

The North Karelia wellbeing services county is piloting Nightingale's blood analysis technology.

Nightingale Health
Press release12/18/2025, 1:00 PM

North Karelia Wellbeing Services County adopts Nightingale Health’s disease risk assessment as part of public healthcare in Finland

Nightingale Health
New study on benefits of Nightingale blood test in identifying cardiovascular disease risk
Analyst Comment12/18/2025, 8:14 AM by
Antti Luiro, Antti Siltanen

New study on benefits of Nightingale blood test in identifying cardiovascular disease risk

A new study shows that the company's blood test can improve the detection of risk factors for heart attacks and strokes.

Nightingale Health
Press release12/17/2025, 7:30 AM

Landmark study: Nightingale Health’s blood test can improve prevention of heart attacks and strokes by 44% compared to current clinical practice

Nightingale Health
Life Science Companies as Investments | Life Science Night Dec. 9, 202514:40
Video12/16/2025, 7:30 AM

Life Science Companies as Investments | Life Science Night Dec. 9, 2025

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia TechnologiesBioretecBiohitFaron PharmaceuticalsModulightNexstimOrionBittiumDetection TechnologyOptomedRevenio GroupNightingale HealthHerantis PharmaNanoform Finland
Changes in Nightingale’s management team continue
Analyst Comment12/15/2025, 7:59 AM by
Antti Luiro, Antti Siltanen

Changes in Nightingale’s management team continue

In light of the news, Nightingale is rebuilding its management team to better accelerate growth in its healthcare business.

Nightingale Health